Company intelligence / Profile preview

Nanovex Biotechnologies

Llanera, Asturias, Spainnanovexbiotech.com ↗

Ownership: Private
Development stage: Other

Overview

Nanovex Biotechnologies develops innovative drug delivery nanosystems, such as liposomes and nanoparticles, enhancing stability, bioavailability, and targeted delivery. Their systems have demonstrated significant efficacy improvements—including in skin penetration and dermal restoration—though they are primarily R&D and technology platform providers rather than developers of proprietary therapeutics

Therapeutic areas: ImmunologyInfectious DiseasesRare DiseasesDermatologyOncology
Modalities: NanoparticleLiposomeNanovesicleMetallic nanoparticlesSmall unilamellar vesiclesCationic liposomesNiosomeBiologicOligonucleotide
Industry: Drug Discovery Services

Partnerships

OLIGOFASTX consortium (with Sylentis/PharmaMar Group and other Spanish firms for oligonucleotide drug delivery)European Commission research grants

Beyond the preview

Go deeper on Nanovex Biotechnologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanovex Biotechnologies.